Axinix

Axitinib is an oral tyrosine kinase inhibitor selective for vascular endothelial growth factor (VEGF) receptors -1, -2 and -3 that is used in the therapy of advanced Renal Cell Carcinoma (RCC). Axitinib prevents the progression of cancer by inhibiting angiogenesis and blocking tumor growth.

Slider 1 Slider 2 Slider3

300+
Total Product

85+
Oncology Products

114+
Country
with our customers

20
Anti Viral

GLOBAL PATIENT SUPPORT PROGRAM

Life saving drugs are either beyond the reach of general people or not available in many countries. Because of the patient exemptions for Bangladeshi companies,Beacon Pharmaceuticals can manufacture the patented drugs. As a support to global patient.

REGISTERED & LICENSED BY REGULATORY AUTHORITY OF BANGLADESH

Axinix 1: Drug Registration Number: 341-324-010 Inclusion Date: 15-10-2017 Valid up to: 14-10-2022

Axinix 5: Drug Registration Number: 341-325-010 Inclusion Date: 10-10-2017 Valid up to: 14-10-2022